FDA ex­plains plans for new phar­ma­ceu­ti­cal qual­i­ty as­sess­ment sys­tem

As part of its work to im­prove and mod­ern­ize the qual­i­ty as­sess­ment of drug ap­pli­ca­tions, the FDA is de­vel­op­ing a new, more stan­dard­ized sys­tem, to be known as the Knowl­edge-aid­ed As­sess­ment & Struc­tured Ap­pli­ca­tion (KASA), ac­cord­ing to an ar­ti­cle au­thored by of­fi­cials from the FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search and pub­lished in the lat­est is­sue of the In­ter­na­tion­al Jour­nal of Phar­ma­ceu­tics.

The au­thors de­scribe KASA as a new sys­tem that cap­tures and man­ages in­for­ma­tion in a struc­tured for­mat about the in­her­ent risk and con­trol ap­proach­es for prod­uct de­sign, man­u­fac­tur­ing and fa­cil­i­ties.

The sys­tem is meant to help the FDA ad­dress chal­lenges re­lat­ed to its qual­i­ty as­sess­ments. The au­thors note that when a qual­i­ty as­ses­sor cur­rent­ly re­views a reg­u­la­to­ry ap­pli­ca­tion, “it is not pos­si­ble to eas­i­ly lo­cate his­tor­i­cal da­ta about sim­i­lar prod­ucts, process­es, or the fa­cil­i­ties. Such a prac­tice has sig­nif­i­cant­ly re­duced the ef­fi­cien­cy of the reg­u­la­to­ry as­sess­ment and in­creased the like­li­hood of in­con­sis­ten­cies. Fur­ther, in par­tic­u­lar­ly ur­gent cas­es, the FDA may not have read­i­ly avail­able up-to-date in­for­ma­tion to pro­vide time­ly, thor­ough, and com­plete re­spons­es, hin­der­ing the FDA’s reg­u­la­to­ry over­sight.”

But with KASA, cer­tain rules and al­go­rithms will be able to es­ti­mate the ini­tial in­her­ent prod­uct and man­u­fac­tur­ing risks.

“Af­ter the as­ses­sor en­ters in­for­ma­tion in the sys­tem based on the ap­pli­ca­tion, a fail­ure modes, ef­fects and crit­i­cal­i­ty analy­sis (FME­CA) ap­proach is em­ployed. This is used to ob­jec­tive­ly and quan­ti­ta­tive­ly as­sess and rank risks as­so­ci­at­ed with the fail­ure modes of drug prod­uct de­sign and man­u­fac­tur­ing. These are the risks that have the great­est chance of caus­ing prod­uct and man­u­fac­tur­ing fail­ure or un­ex­pect­ed harm to the pa­tient,” FDA of­fi­cials ex­plain.

KASA al­so will help with risk con­trols re­lat­ed to prod­uct de­sign and man­u­fac­tur­ing.

In ad­di­tion, the CDER of­fi­cials note that al­though KASA is be­ing pri­mar­i­ly de­vel­oped as an as­sess­ment tool, “it is ca­pa­ble of al­le­vi­at­ing prob­lems” as­so­ci­at­ed with the sub­mis­sion of drug ap­pli­ca­tions via the elec­tron­ic com­mon tech­ni­cal doc­u­ment (eCTD) for­mat.

In the fu­ture, the sub­mis­sion struc­ture rec­om­men­da­tions, such as those ini­ti­at­ed for stan­dard­iza­tion of Phar­ma­ceu­ti­cal Qual­i­ty/Chem­istry Man­u­fac­tur­ing and Con­trol (PQ/CMC) da­ta and ter­mi­nolo­gies could be made to in­ter­face with KASA’s struc­tured as­sess­ment ap­proach. “Un­der this par­a­digm, au­to­mat­ed tools would be used to pop­u­late the KASA tem­plate from the struc­tured sub­mis­sion with, for ex­am­ple, spec­i­fi­ca­tions and crit­i­cal process pa­ra­me­ter ranges,” the ar­ti­cle notes.

As far as the ma­jor ben­e­fits of this shift to a KASA sys­tem, the au­thors note that it “moves reg­u­la­to­ry ap­pli­ca­tion as­sess­ment from the cur­rent un­struc­tured text doc­u­ment to an is­sue-based reg­u­la­to­ry and tech­ni­cal as­sess­ment us­ing struc­tured da­ta and in­for­ma­tion with stan­dard for­mat­ting, a com­mon vo­cab­u­lary, and a uni­form out­put. In turn, this im­proves con­sis­ten­cy, trans­paren­cy, com­mu­ni­ca­tion, and ob­jec­tiv­i­ty of reg­u­la­to­ry ac­tions, as well as knowl­edge man­age­ment with­in the Agency.”

So, when is KASA com­ing?

The ar­ti­cle did not pro­vide a time­line, but the FDA said last Sep­tem­ber that a draft guid­ance would be re­leased for in­dus­try com­ment be­fore any­thing takes ef­fect.

Ar­ti­cle


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Novartis CEO Vas Narasimhan (via AP Images)

Go­ing 0-for-4 on a big PhI­II pro­gram, No­var­tis scraps their top asth­ma prospect and sig­nal big trou­ble for a lit­tle biotech

Novartis this morning reported that their asthma drug fevipiprant flunked two more Phase III studies, crushing their hopes in what had been a star H2 development program at the pharma giant.

Back in October Novartis buried the news that fevipiprant had failed the first 2 Phase III studies in their Q3 report, noting a lack of success in scoring an improvement in FEV1 among moderate patients. But the pharma giant immediately shifted focus to LUSTER 1 and 2 in moderate to severe patients, noting that they were the core studies needed for registration and a blockbuster future.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Amarin CEO John Thero discussing the company's plans for Vascepa, August 2019 — via Bloomberg

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

For all those people who could never quite believe that Amarin $AMRN would get an expanded label with blockbuster implications, the stress and anxiety on display right up to the last minute on Twitter can now end. But new, pressing questions will immediately surface now that the OK has come through.

On Friday afternoon, the FDA stamped its landmark approval on the industrial strength fish oil for reducing cardio risks for a large and well defined population of patients. The approval doesn’t give Amarin everything it wants in expanding its use, losing out on the primary prevention group, but it goes a long way to doing what the company needed to make a major splash. The approval was cited for patients with “elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

Sarepta has a friend in the FDA after all. Four months after the agency determined that it would be wrong to give Sarepta an accelerated approval for their Duchenne MD drug golodirsen, regulators have executed a stunning about face and offered the biotech a quick green light in any case.

It was the agency that first put out the news late Thursday, announcing that Duchenne MD patients with a mutation amenable to exon 53 skipping will now have their first targeted treatment: Vyondys 53, or golodirsen. Having secured the OK via a dispute resolution mechanism, the biotech said the new drug has been priced on par with their only other marketed drug, Exondys 51 — which for an average patient costs about $300,000 per year, but since pricing is based on weight, that sticker price can even cross $1 million.

Sarepta shares $SRPT surged 23% after-market to $124.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Paul Biondi (File photo)

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete break­down

Paul Biondi was never afraid to bet big during his stint as business development chief at Bristol-Myers Squibb. And while the gambles didn’t all pay out, by any means, his roster of pacts illustrates the broad ambitions the pharma giant has had over the last 5 years — capped by the $74 billion Celgene buyout.

On Thursday, we learned that Biondi had exited the company. And Chris Dokomajilar at DealForma came up with the complete breakdown on every buyout, licensing pact and product purchase Bristol-Myers forged during his tenure in charge of the BD team at one of the busiest companies in biopharma.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Biondi (File photo)

Bris­tol-My­er­s' strat­e­gy, BD chief Paul Bion­di ex­it­ed the com­pa­ny — just ahead of the $74B Cel­gene deal close

Paul Biondi, who orchestrated billions of dollars in deals for Bristol-Myers Squibb over the 5 years he’s run their business development team, has exited the company. Biondi left last month, according to a company spokesperson, in pursuit of another — unspecified — external opportunity.

After 17 years with Bristol-Myers Squibb, Paul Biondi, Head of Strategy and Business Development, decided to leave the company to pursue an external opportunity. The company wishes him well in his new endeavors. Bristol-Myers Squibb  is actively searching for Paul’s successor, and will make an announcement, as appropriate.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Arie Belldegrun at UKBIO 2019. Shai Dolev for Endpoints News

Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

Two days after Kite Pharma founder Arie Belldegrun told a federal courtroom that a meeting he had with a Memorial Sloan Kettering executive wasn’t about licensing their immunotherapy patent, Kite’s ex-CEO Aya Jakobovits said it was.

The admission came Tuesday during cross-examination in a patent infringement case that features two of the biggest cancer biotechs and some of the most well-known names in American medicine.

Jakobovits initially said she was not in attendance, didn’t know it was going to happen and didn’t know what took place, according to Law360. But then the plaintiff’s lawyer handed her a document – whose contents were not publicly revealed – and asked again if she learned after-the-fact that the meeting involved a potential patent license.

“Yes,” Jakobovits eventually said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to the fin­ish line

Three days after Gilead’s Kite subsidiary showed off stellar data on their number 2 CAR-T KTE-X19 at ASH, the executive team has pivoted straight to the FDA with a BLA filing and a shot at a near-term approval.

In a small, 74-patient Phase II trial reported out at the beginning of the week, investigators tracked a 93% response rate with two out of three mantle cell lymphoma patients experiencing a complete response.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

Given the way the FDA has been whisking through new drug approvals months ahead of their PDUFA date, AstraZeneca and their partners Daiichi Sankyo may not have to wait until Q2 of next year to get a green light on trastuzumab deruxtecan (DS-8201).

The pharma giant this morning played their ace in the hole, showing off why they were willing to commit to a $6.9 billion deal — with $1.35 billion in a cash upfront — to partner on the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Arie Belldegrun (Photo: Jeff Rumans for Endpoints News)

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

A Kite deal that’s already become a burden on Gilead’s back just got heavier as a California jury has ruled Gilead must pay Bristol-Myers Squibb and Sloan Kettering $585 million plus a 27.6% royalty for patent infringement committed by its subsidiary: about $752 million in total.  The ruling is almost certain to be appealed.

Kite Pharma — founded by Arie Belldegrun, now focused on a next-gen CAR-T company — has been facing a lawsuit since the day its first CAR–T therapy won approval in October, 2017. Juno Therapeutics and Sloan Kettering filed a complaint saying Kite had copied its technology. Gilead acquired Kite in June of that year for $11.9 billion.  Juno was acquired the following year by Celgene for $9 billion, before Celgene was acquired by Bristol-Myers Squibb in 2019.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.